New research sees funding gap leading to further consolidatin of biotech industry

21 May 2009

The depth and virulence of the financial crisis means that the funding model for the biotechnology industry will have to change, leading to a  period of increased consolidation, according to the latest annual  biotechnology report issued by Marks & Clerk, a leading, UK-based  intellectual property firm.

The study, based on an international survey of 365 executives across  the biotechnology and pharmaceutical sectors, also reveals a widespread  belief that US President Barack Obama's recently-announced initiatives  and reforms will strengthen the position of the US as a center for the  industry, providing a further threat to Europe and the UK in  particular. Britain currently enjoys a strong position within the  industry, which Chancellor of the Exchequer Alistair Darling is looking  to boost via the newly-created Strategic Investment Fund announced in  the Budget.

Lack of appetite for risk

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight